SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BLSM

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$14.51+$0.10 (+0.69%)
 
Market cap
$422M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 7, 2026
Market Cap$421.97M-9.3%
Revenue (ttm)$0
Net Income-$68.78M
EPS-$10.35
Shares Out29.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume270,735
Open$14.34
Previous Close$14.41
Day's Range$13.90 - $15.63
52-Week Range$11.02 - $27.99
Betan/a
AnalystsBuy
Price Target$38.33(+164.16%)
Earnings DateFeb 11, 2027

About BLSM

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Address
10255 Science Center Drive, Suite 200, San Diego, CA, 92121, US
Market Cap
422 million
Employees
69
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$25.18M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$11.36$19.76$28.16SepNov

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $35.00 (+141.2%)

2 firms rating BLSM in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From BLSM’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+0.69%
5 Days
+3.64%
1 Month
-6.99%
6 Months
-9.31%
1 Year
-9.31%

$BLSM stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BLSM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BLSM's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BLSM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BLSM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BLSM from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BLSM

VTIVanguard Morningstar Total Stock Market ETF$3.43M
VXFVanguard Extended Market ETF$1.49M
VTWOVanguard Russell 2000 ETF$130.56K
VTWGVanguard Russell 2000 Growth ETF$13.08K
VTWVVanguard Russell 2000 Value ETF$4.81K
VTHRVanguard Russell 3000 ETF$1.87K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BLSM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
85.76
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Multiple positive clinical catalysts including FDA alignment on dosage and Phase 2 advancement; strong pipeline progress in oncology programs.

Recent Insider Activity

Buys
7
Sells
0
Buy Value
$25.18M
Distinct Buyers
6

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.